drugset / Trial / NCT05308264
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
NaSequentialOpen-labelTreatment
Summary
Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)
Timeline
- Start
- 2022-09-12
- Primary completion
- 2026-08
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | R906289 | Unknown | 250 mg | Oral |
| Subject | R906289 | Unknown | 500 mg | Oral |
| Subject | R906289 | Unknown | 750 mg | Oral |